# A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

> **NCT05469100** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 37 (actual)

## Conditions studied

- Healthy
- Renal Insufficiency

## Interventions

- **DRUG:** Selpercatinib

## Key facts

- **NCT ID:** NCT05469100
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469100, "A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05469100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*